Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.40 |
| ▸ | CDK1 | P06493 | 2/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.36 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.35 |
| ▸ | DHFR | P00374 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6403131 | 1.00 | TLR8 (0.40) | TLR8CDK1CCNB1TSHRMCHR1 | |
| SCHEMBL6397725 | 1.00 | TLR8 (0.40) | TLR8CDK1CCNB1TSHRMCHR1 | |
| SCHEMBL6402618 | 0.94 | TLR8 (0.37) | TLR8CDK1CCNB1TSHRMCHR1 | |
| SCHEMBL6403682 | 0.82 | ALDH1A1 (0.41) | TLR8TSHR | |
| SCHEMBL6402675 | 0.80 | MAPT (0.38) | TLR8CDK1CCNB1TSHRMCHR1 | |
| SCHEMBL8689288 | 0.80 | MEN1 (0.38) | TLR8CDK1CCNB1TSHRMCHR1 | |
| SCHEMBL7121610 | 0.80 | DNM2 (0.33) | TLR8CDK1CCNB1TSHRNOS1 | |
| SCHEMBL7117869 | 0.80 | DNM2 (0.33) | TLR8CDK1CCNB1TSHRNOS1 | |
| SCHEMBL7122685 | 0.80 | DNM2 (0.33) | TLR8CDK1CCNB1TSHRNOS1 | |
| SCHEMBL7121624 | 0.80 | DNM2 (0.33) | TLR8CDK1CCNB1TSHRNOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0356271-B1 | 2,4-Diamino-pyrimidine-3-oxide derivatives and their use in the treatment and the prevention of hair drop | OREAL (FR) | 1995-04-05 | — | — | EP | claimed |
| US-4973474-A | 2,4-diaminopyrimidine 3-oxide derivatives and their use for the treatment and prevention of hair loss | L'OREAL (FR) | 1990-11-27 | — | — | US | claimed |
| US-20050049232-A1 | Composition | LINDAU PAR (SE) | 2005-03-03 | — | — | US | disclosed |
| EP-1463483-A1 | NEW COMPOSITION | Ponsus Pharma AB (SE) | 2004-10-06 | — | — | EP | disclosed |
| WO-2003055454-A1 | NEW COMPOSITION | PONSUS PHARMA AB (SE) | 2003-07-10 | — | — | WO | disclosed |
| US-4973474-A | 2,4-diaminopyrimidine 3-oxide derivatives and their use for the treatment and prevention of hair loss | L'OREAL (FR) | 1990-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049232-A1 | Composition | CUTA, LIPG, LIPA | TLR8 2389/4885CDK1 3554/4885CCNB1 1533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.